parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in bergmann glia	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 14794

HEPACAM in dopamine neurons, braak+0.25 (p 0.514) → -0.18 (p 0.646)receipt 14802
HEPACAM in astrocytes, braak+0.41 (p 0.277) → +0.08 (p 0.838)receipt 14801

receipt 14802: HEPACAM in dopamine neurons, braak

power: full sample +0.02 (p 0.935, n 18), 95% CI -0.45 to +0.48. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.800, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.05 (p 0.834, n 18). could be the mix.
skeptic: leave-one-out range -0.10 to +0.15, sign flips 7; without severely affected donors +0.02 (p 0.935, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for HEPACAM in dopamine neurons.

case closed: nothing better to follow up.

receipt 14801: HEPACAM in astrocytes, braak

power: full sample +0.28 (p 0.254, n 18), 95% CI -0.21 to +0.66. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.29 (p 0.235, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.44 (p 0.070, n 18). could be the mix.
skeptic: leave-one-out range +0.18 to +0.37, sign flips 0; without severely affected donors +0.28 (p 0.254, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for HEPACAM in astrocytes.

case closed: nothing better to follow up.

loading the receipts